Array BioPharma, a biopharmaceutical company focused on targeted small molecule drugs to treat cancer, has appointed Michael N. Needle, M.D., as its chief medical officer. 

Needle, a board certified hematologist/oncologist, will oversee clinical development across Array BioPharma's pipeline, including its two wholly-owned cancer drugs, ARRY-520 for multiple myeloma and ARRY-614 for myelodysplastic syndromes, as well as collaborate with strategic partners to advance late-stage programs.

Needle has more than 14 years of pharmaceutical industry experience in drug development and regulatory affairs.  He most recently served as the chief medical officer of the Multiple Myeloma Research Foundation and Consortium (MMRF). Prior to his tenure at MMRF, he held multiple vice president level positions at Celgene in clinical R&D in oncology, strategic medical business development and pediatric strategy. Needle also served as the vice president of clinical affairs at ImClone Systems.